

SLOVENIA

Recent and planned developments in pharmaceutical policies 2017/2018

Special topic: patient involvement in pricing and reimbursement of medicines

CHANGES IN PRICING

- regular semi-annual price reviews (external price referencing for all medicines that are financed from public funds or intended to finance from public funds - 4200) - ongoing

CHANGES IN REIMBURSEMENT

- Therapeutic reference pricing system for therapeutic groups of medicines (new groups 30.11.2017: medicinal products containing inhaled corticosteroids and combination medicinal products with adrenergic agonists and inhaled corticosteroids)

OTHERS CHANGES

- new Health Care and Health Insurance Act under consideration

PATIENT INVOLVEMENT IN PRICING AND REIMBURSEMENT OF MEDICINES

Pricing and reimbursement procedures of medicines

- Do patients/citizens have the opportunity to raise their voice during medicines pricing and/or reimbursement procedures? **NO**
- Do patients also have the opportunity for participation in review/appeal processes? **NO**

Related to HTA procedures

- Do patients have the opportunity to raise their voice in HTA procedures? **NO**

Before the adoption of any regulation, a public debate is planned on the e-democracy portal. Anyone can make comments on which the answer is mandatory. No comments have to be considered.